FDA holds first meeting on peptides as supplement ingredients under RFK Jr., Stanford unveils peptide-to-DNA sequencing, and Skeptic Magazine warns of risks.
10 stories · Covering regulatory, industry, research
Today's peptide news is dominated by a historic FDA public meeting on whether peptides should be allowed as dietary supplement ingredients — the first such meeting under HHS Secretary RFK Jr., who has vowed to "end the war on supplements and peptides." The move is drawing both enthusiasm and sharp criticism, with Skeptic Magazine calling the impending deregulation of ~14 compounds "one of the biggest medical experiments in the history of America." Meanwhile, the Washington Post published a comprehensive guide to what GLP-1 drugs actually do to the body beyond weight loss, and Stanford researchers unveiled a breakthrough "reverse translation" technique that converts peptide sequences into DNA for ultra-fast sequencing.
The FDA held a public meeting to discuss broadening supplement ingredient criteria to include peptides, probiotics, and other substances. This is the first such meeting since RFK Jr. became HHS Secretary.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
A condition-by-condition guide examining what's proven, promising, and untested for GLP-1 drugs beyond weight loss — covering cardiovascular disease, addiction, kidney disease, and neurological conditions.
Stanford researchers developed a method converting peptide sequences into DNA for standard sequencing, published in Nature Biotechnology. Could dramatically accelerate peptide drug discovery.
Kumamoto University researchers developed cyclic peptide D-DNP-V that escorts insulin through the gut, achieving one-third to nearly half the effectiveness of injected insulin in mice.
J&J's icotrokinra (Icotyde) approved for moderate-to-severe plaque psoriasis, with ~70% of patients achieving clear or almost clear skin by week 16.
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.
Report examining viral social media claims about peptides promising DNA repair, nerve relief, and wound healing, referencing RFK Jr.'s Joe Rogan appearance supporting peptide access.
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.